Microparticles-entrapped micelles: a novel delivery system to improve solubility and dissolution rate of poorly water-soluble valsartan

References

• Alanazi FK, El-Badry M, Ahmed MO, Alsarra IA. Improvement of Albendazole dissolution by preparing microparticles using spray-drying technique. Sci Pharma, 2007;75:63–79
   Google Scholar
• Banerjee R, Chakraborty H, Sarkar M. Host-guest complexation of oxicam NSAIDs with β cyclodextrin. Biopolymers, 2004;75:355–65
   PubMed Web of Science ®Google Scholar
• Bastin RJ, Bowker MJ, Slater BJ. Salt selection and optimization procedure for pharmaceutical new chemical entities. Org Process Res Dev, 2000;4:427–35
   Web of Science ®Google Scholar
• Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther, 1997;62:272–8
   PubMed Web of Science ®Google Scholar
• Chowdhary KPR, Rao KSP. Factorial studies on the effects of β-Cyclodextrin and Poloxamer 407 on the solubility and dissolution rate of BCS Class II Drugs. Int J Pharm Res and Dev, 2011;3:125–30
   PubMedGoogle Scholar
• Christiansen A, Backensfeld T, Weitschies W. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes. Euro J Pharma Sci, 2010;41:376–82
   PubMed Web of Science ®Google Scholar
• De Souza MC, Marchetti JM. Development of albendazole sulfoxide-loaded Eudragit microparticles: A potential strategy to improve the drug bioavailability. Adv Powder Tech, 2012;23:801–7
   Web of Science ®Google Scholar
• Dixit AR, Rajput SJ, Patel SG. Preparation and bioavailability assessment of SMEDDS containing valsartan. AAPS PharmSciTech, 2010;11:314–21
   PubMed Web of Science ®Google Scholar
• Doney JA. 2008. Amorphous valsartan and the production thereof-International Application PCT/US2007/087335
   Google Scholar
• Flesch, G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol, 1997;52:115–20
   PubMed Web of Science ®Google Scholar
• Gupta U, Agashe HB, Asthana A, Jain NK. Dendrimers: Novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules, 2006;2:649–58
   Google Scholar
• Hsu JP, Nacu A. Behavior of soybean oil-in-water emulsion stabilized by nonionic surfactant. J Colloid Interface Sci, 2003;259:374–81
   PubMed Web of Science ®Google Scholar
• ICH Guideline: Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products, U.S. Department of Health and Human Services, Food and Drug Administration, November 2003, Revision 2
   Google Scholar
• Jensen CEM, Santos RAS, Denadai AML, Santos CFF, Braga ANG, Sinisterra RD. Pharmaceutical composition of valsartan: β-Cyclodextrin: physico-chemical characterization and anti- hypertensive evaluation. Molecules, 2010;15:4067–84
   PubMed Web of Science ®Google Scholar
• Kshirsagar SJ, Bhalekar MR, Sable Preeti N, Wadekar S, Madgulkar AR. Dissolution improvement of poorly water soluble drug using dry emulsion and solid dispersion. J Pharmacy Res, 2009;2:1780–5
   Google Scholar
• Kumar KV, Arunkumar N, Verma PRP, Rani C. Preparation and in vitro characterization of valsartan solid dispersions using skimmed milk powder as carrier. Int J PharmTech Res, 2009;1:431–7
   Google Scholar
• Liu R. ed. 2008. Water insoluble drug formulation. New York, USA: CRC Press, Taylor & Francis group, pp. 133–467
   Google Scholar
• Loftsson T, Brewster ME, Masson M. Role of cyclodextrins in improving oral drug delivery. AM J Drug Deliv, 2004;2:261–75
   Google Scholar
• Mahapatra AK, Murthy PN, Biswal S, Mahapatra APK, Pradhan SP. Dissolution enhancement and physicochemical characterization of valsartan in solid dispersions with β- CD, HP β- CD and PVP K- 30. Dissolution Technol February, 2011;18(1):39–45
   Web of Science ®Google Scholar
• Marques M. Dissolution media simulating fasted and fed states. Dissolution Technol, 2004;11(2):16
   Google Scholar
• Momot KI, Kuchel, PW, Chapman BE, Deo P, Whittaker D. NMR Study of the association of propofol with nonionic surfactants. Langmuir, 2003;19:2088–95
   Web of Science ®Google Scholar
• Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharmaceut Technol, 1996;20:64–74
   Google Scholar
• Naveen C, Shastri N, Rama Rao T. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm Sin B, 2012;2:502–8
   Google Scholar
• Park YJ, Lee HK, Bin IY, Lee W, Han HK. Improved pH-Independent dissolution and oral absorption of valsartan via the preparation of solid dispersion. Arch Pharm Res, 2010;33:1235–40
   PubMed Web of Science ®Google Scholar
• Rangel-Yagui CO, Pesoa Jr A, Tavares LC. Micellar solubilization of drugs. J. Pharm Pharmaceut Sci, 2005;8:147–63
   PubMed Web of Science ®Google Scholar
• Sahoo NG, Kakran M, Li L, Judeh Z. Fabrication of composite microparticles of artemisinin for dissolution enhancement. Powder Technol, 2010;203:277–87
   Web of Science ®Google Scholar
• Shrivastava AR, Ursekar B, Kapadia CJ. Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets. Curr Drug Deliv, 2009;6:28–37
   PubMedGoogle Scholar
• Tapas AR, Kawtikwar PS, Sakarkar DM. Spherically agglomerated solid dispersions of valsartan to improve solubility, dissolution rate and micromeritic properties. Int J Drug Deliv, 2010;2:304–13
   Google Scholar
• Wikarsa S, Durand D, Delarbre JL, Baylac G, Bataille B. The improvement of ibuprofen dissolution rate through microparticles spray-drying processed in an aqueous system. Drug Dev Ind Pharm, 2008;34:485–91
   PubMed Web of Science ®Google Scholar
• Wong SM, Kellaway IW, Murdan S. Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 2006;317:61–8
   PubMed Web of Science ®Google Scholar
• Yamada I, Goda T, Kawata M, Shiotuki T, Ogawa K. Gastric acidity-dependent bioavailability of commercial sustained release preparations of indomethacin, evaluated by gastric acidity-controlled beagle dogs. Chem Pharm Bull, 1990;38:3112–15
   PubMed Web of Science ®Google Scholar